期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 60, 期 3, 页码 939-947出版社
IOS PRESS
DOI: 10.3233/JAD-161284
关键词
Alzheimer's disease; mild cognitive impairment; prognosis; PET; volumetric MRI
资金
- National Institute of Health [R01AG017761, R01AG041795, K23MH105688]
- NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH105688] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG041795, R01AG017761] Funding Source: NIH RePORTER
This project compares three neuroimaging biomarkers to predict progression to dementia in subjects with mild cognitive impairment (MCI). Eighty-eight subjects with MCI and 40 healthy controls (HCs) were recruited. Subjects had a 3T magnetic resonance imaging (MRI) scan, and two positron emission tomography (PET) scans, one with Pittsburgh compound B ([C-11] PIB) and one with fluorodeoxyglucose ([F-18] FDG). MCI subjects were followed for up to 4 y and progression to dementia was assessed on an annual basis. MCI subjects had higher [C-11] PIB binding potential (BPND) than HCs in multiple brain regions, and lower hippocampus volumes. [C-11] PIB BPND, [F-18] FDG standard uptake value ratio (SUVR), and hippocampus volume were associated with time to progression to dementia using a Cox proportional hazards model. [F-18] FDG SUVR demonstrated the most statistically significant association with progression, followed by [C-11] PIB BPND and then hippocampus volume. [C-11] PIB BPND and [F-18] FDG SUVR were independently predictive, suggesting that combining these measures is useful to increase accuracy in the prediction of progression to dementia. Hippocampus volume also had independent predictive properties to [C-11] PIB BPND, but did not add predictive power when combined with the [F-18] FDG SUVR data. This work suggests that PET imaging with both [C-11] PIB and [F-18] FDG may help to determine which MCI subjects are likely to progress to AD, possibly directing future treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据